Incidence and Prevalence of Glaucoma, Corticosteroid Response, and Ocular Hypertension in Uveitis and its Anatomical Subtypes

IF 4.2 1区医学 Q1 OPHTHALMOLOGY

American Journal of Ophthalmology Pub Date : 2025-06-04 DOI:10.1016/j.ajo.2025.05.046

RAYNA F. MARSHALL , DANIEL LEE , JENNIFER E. THORNE , MONA KALEEM , MEGHAN K. BERKENSTOCK

{"title":"Incidence and Prevalence of Glaucoma, Corticosteroid Response, and Ocular Hypertension in Uveitis and its Anatomical Subtypes","authors":"RAYNA F. MARSHALL , DANIEL LEE , JENNIFER E. THORNE , MONA KALEEM , MEGHAN K. BERKENSTOCK","doi":"10.1016/j.ajo.2025.05.046","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>Uveitic glaucoma represents one of the most serious, sight-threatening complications of ocular inflammatory disorders. In this study, we assessed the cumulative and yearly prevalence and incidence of uveitic glaucoma in the TriNetX United States (US) Collaborative Network, a database composed of over 100 million patient medical records.</div></div><div><h3>Design</h3><div>Incidence, Prevalence, and Trend study.</div></div><div><h3>Participants</h3><div>Subjects with uveitic glaucoma in the TriNetX database.</div></div><div><h3>Methods</h3><div>A retrospective study of a uveitic-glaucoma cohort, identified with patients having both ICD-10 codes of uveitis and glaucoma, ocular hypertension, or corticosteroid response diagnosed on the same day or after the onset of uveitis, was conducted using the TriNetX US database. Demographic information as well as cumulative and yearly incidence and prevalence of uveitic glaucoma were determined.</div></div><div><h3>Main Outcome Measures</h3><div>Cumulative and yearly incidence and prevalence of uveitic glaucoma, between 2013-2022. A sub-analysis of uveitic glaucoma by uveitis anatomic location was also conducted.</div></div><div><h3>Results</h3><div>30,681 patients with uveitic glaucoma were identified. The average age of the cohort at presentation was 67 years (SD = 19, 95% CI 66.8-67.2 years); 55.0% (n = 16 875, 95% CI 54.4-55.9%) were female and 50.7% (n = 15 555, 95% CI 50.1-51.3%) were Caucasian. Among the uveitis population, 15.5% of patients developed glaucoma in the 10-year time period (n = 30 681, 95% CI 15.3-15.6%). The cumulative incidence of uveitic glaucoma was 5 per 100 000 and the cumulative prevalence was 27 per 100,000 between 2013 and 2022. During the study period, the incidence and prevalence of uveitic glaucoma decreased. Patients with both anterior and intermediate uveitis (n = 529; 20.3%, 95% CI 18.8-21.9%) had the highest rates of uveitic glaucoma, followed by anterior (n = 20 849; 16.4%, 95% CI 16.2-16.7%), panuveitis (n = 48; 11.6%, 95% CI 8.5-14.7%), endophthalmitis (n = 273; 11.3%, 95% CI 10.9-11.7%), intermediate (n = 173; 10.0%, 95% CI 8.6-11.5%), and posterior (n = 1579; 8.2%, 95% CI 7.8-8.6%). Anterior and intermediate uveitis patients also had the highest rates of ocular hypertension (n = 465; 17.9%, 95% CI 16.4-19.3%) and corticosteroid response (n = 279; 10.7%, 95% CI 9.5-11.9%).</div></div><div><h3>Conclusions</h3><div>Since 2013, the incidence and prevalence rates of uveitic glaucoma have been decreasing. Patients with both anterior and intermediate uveitis patients had the highest relative rates of glaucoma compared to other uveitis subtypes.</div></div>","PeriodicalId":7568,"journal":{"name":"American Journal of Ophthalmology","volume":"278 ","pages":"Pages 13-21"},"PeriodicalIF":4.2000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002939425002855","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

Uveitic glaucoma represents one of the most serious, sight-threatening complications of ocular inflammatory disorders. In this study, we assessed the cumulative and yearly prevalence and incidence of uveitic glaucoma in the TriNetX United States (US) Collaborative Network, a database composed of over 100 million patient medical records.

Design

Incidence, Prevalence, and Trend study.

Participants

Subjects with uveitic glaucoma in the TriNetX database.

Methods

A retrospective study of a uveitic-glaucoma cohort, identified with patients having both ICD-10 codes of uveitis and glaucoma, ocular hypertension, or corticosteroid response diagnosed on the same day or after the onset of uveitis, was conducted using the TriNetX US database. Demographic information as well as cumulative and yearly incidence and prevalence of uveitic glaucoma were determined.

Main Outcome Measures

Cumulative and yearly incidence and prevalence of uveitic glaucoma, between 2013-2022. A sub-analysis of uveitic glaucoma by uveitis anatomic location was also conducted.

Results

30,681 patients with uveitic glaucoma were identified. The average age of the cohort at presentation was 67 years (SD = 19, 95% CI 66.8-67.2 years); 55.0% (n = 16 875, 95% CI 54.4-55.9%) were female and 50.7% (n = 15 555, 95% CI 50.1-51.3%) were Caucasian. Among the uveitis population, 15.5% of patients developed glaucoma in the 10-year time period (n = 30 681, 95% CI 15.3-15.6%). The cumulative incidence of uveitic glaucoma was 5 per 100 000 and the cumulative prevalence was 27 per 100,000 between 2013 and 2022. During the study period, the incidence and prevalence of uveitic glaucoma decreased. Patients with both anterior and intermediate uveitis (n = 529; 20.3%, 95% CI 18.8-21.9%) had the highest rates of uveitic glaucoma, followed by anterior (n = 20 849; 16.4%, 95% CI 16.2-16.7%), panuveitis (n = 48; 11.6%, 95% CI 8.5-14.7%), endophthalmitis (n = 273; 11.3%, 95% CI 10.9-11.7%), intermediate (n = 173; 10.0%, 95% CI 8.6-11.5%), and posterior (n = 1579; 8.2%, 95% CI 7.8-8.6%). Anterior and intermediate uveitis patients also had the highest rates of ocular hypertension (n = 465; 17.9%, 95% CI 16.4-19.3%) and corticosteroid response (n = 279; 10.7%, 95% CI 9.5-11.9%).

Conclusions

Since 2013, the incidence and prevalence rates of uveitic glaucoma have been decreasing. Patients with both anterior and intermediate uveitis patients had the highest relative rates of glaucoma compared to other uveitis subtypes.

查看原文本刊更多论文

葡萄膜炎及其解剖亚型中青光眼、皮质类固醇反应和高眼压的发病率和患病率。

目的：葡萄膜性青光眼是眼部炎症性疾病中最严重、威胁视力的并发症之一。在这项研究中，我们评估了TriNetX美国（US）协作网络中青光眼的累积和年患病率和发病率，该网络是一个由超过1亿例患者医疗记录组成的数据库。设计：发生率、患病率和趋势研究。参与者：TriNetX数据库中的青光眼患者。方法：使用TriNetX美国数据库，对葡萄膜-青光眼队列进行回顾性研究，确定在葡萄膜炎发病当天或发病后诊断为葡萄膜炎和青光眼的ICD-10编码、眼压过高或皮质类固醇反应的患者。确定了人口统计信息以及青光眼的累积和年发病率和患病率。主要结局指标：2013-2022年间青光眼的累积和年发病率和患病率。并对葡萄膜炎解剖位置对葡萄膜性青光眼进行亚分析。结果：共发现30681例青光眼患者。患者就诊时的平均年龄为67岁（SD= 19, 95% CI 66.8-67.2岁）；55.0% （n= 16875, 95% CI 54.1 -55.9%）为女性，50.7% （n= 155555, 95% CI 50.1-51.3%）为白种人。在葡萄膜炎人群中，15.5%的患者在10年期间发生青光眼（n=30,681, 95% CI 15.3-15.6%）。2013-2022年青光眼累计发病率为5 / 10万，累计患病率为27 / 10万。研究期间，青光眼的发病率和患病率均有所下降。前、中期葡萄膜炎患者(n=529；20.3%, 95% CI 18.8-21.9%)的青光眼发生率最高，其次是前眼(n=20,849；16.4%, 95% CI 16.2-16.7%)，全葡萄膜炎(n=48；11.6%, 95% CI 8.5-14.7%)，眼内炎(n=273；11.3%, 95% CI 10.9-11.7%)，中级(n=173；10.0%, 95% CI 8.6-11.5%)和后验(n=1,579；8.2%, 95% ci 7.8-8.6%)。前、中期葡萄膜炎患者的高眼压发生率也最高(n=465；17.9%, 95% CI 16.4-19.3%)和皮质类固醇反应(n=279；10.7%, 95% ci 9.5-11.9%)。结论：2013年以来，青光眼的发病率和患病率呈下降趋势。与其他葡萄膜炎亚型相比，伴有前膜炎和中度葡萄膜炎的患者青光眼的相对发病率最高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American Journal of Ophthalmology 医学-眼科学

CiteScore

9.20

自引率

7.10%

发文量

406

审稿时长

36 days

期刊介绍： The American Journal of Ophthalmology is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and visual science specialists describing clinical investigations, clinical observations, and clinically relevant laboratory investigations. Published monthly since 1884, the full text of the American Journal of Ophthalmology and supplementary material are also presented online at www.AJO.com and on ScienceDirect. The American Journal of Ophthalmology publishes Full-Length Articles, Perspectives, Editorials, Correspondences, Books Reports and Announcements. Brief Reports and Case Reports are no longer published. We recommend submitting Brief Reports and Case Reports to our companion publication, the American Journal of Ophthalmology Case Reports. Manuscripts are accepted with the understanding that they have not been and will not be published elsewhere substantially in any format, and that there are no ethical problems with the content or data collection. Authors may be requested to produce the data upon which the manuscript is based and to answer expeditiously any questions about the manuscript or its authors.